233 related articles for article (PubMed ID: 26552141)
1. [Recent progress of dry powder inhalation of proteins and peptides].
Zhou JY; Zhang L; Mao SR
Yao Xue Xue Bao; 2015 Jul; 50(7):814-23. PubMed ID: 26552141
[TBL] [Abstract][Full Text] [Related]
2. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
Shalash AO; Molokhia AM; Elsayed MM
Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
[TBL] [Abstract][Full Text] [Related]
3. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
[TBL] [Abstract][Full Text] [Related]
5. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose.
Pinto JT; Zellnitz S; Guidi T; Roblegg E; Paudel A
Mol Pharm; 2018 Jul; 15(7):2827-2839. PubMed ID: 29856921
[TBL] [Abstract][Full Text] [Related]
7. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
[TBL] [Abstract][Full Text] [Related]
8. Lactose characteristics and the generation of the aerosol.
Pilcer G; Wauthoz N; Amighi K
Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
[TBL] [Abstract][Full Text] [Related]
9. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
[TBL] [Abstract][Full Text] [Related]
10. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
Shalash AO; Elsayed MMA
AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
[TBL] [Abstract][Full Text] [Related]
11. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
12. Influence of carrier surface fines on dry powder inhalation formulations.
Boshhiha AM; Urbanetz NA
Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
[TBL] [Abstract][Full Text] [Related]
13. [Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].
Liang ZL; Wang XH; Ni R; Zhang L; Muenster U; Mao SR
Yao Xue Xue Bao; 2015 Sep; 50(9):1180-5. PubMed ID: 26757557
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of pollen-shape drug carriers in dry powder inhalation.
Hassan MS; Lau R
J Pharm Sci; 2010 Mar; 99(3):1309-21. PubMed ID: 19862802
[TBL] [Abstract][Full Text] [Related]
15. Relationships between surface coverage ratio and powder mechanics of binary adhesive mixtures for dry powder inhalers.
Rudén J; Frenning G; Bramer T; Thalberg K; Alderborn G
Int J Pharm; 2018 Apr; 541(1-2):143-156. PubMed ID: 29454905
[TBL] [Abstract][Full Text] [Related]
16. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
[TBL] [Abstract][Full Text] [Related]
17. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
18. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
Elsayed MMA; Alfagih IM; Brockbank K; Aodah AH; Ali R; Almansour K; Shalash AO
Int J Pharm; 2024 Apr; 655():123966. PubMed ID: 38452834
[TBL] [Abstract][Full Text] [Related]
19. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
Zeng XM; Martin GP; Marriott C; Pritchard J
J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
[TBL] [Abstract][Full Text] [Related]
20. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
